Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Prevail Therapeutics Inc is a biotechnology business based in the US. Prevail Therapeutics shares (PRVL) are listed on the NASDAQ and all prices are listed in US Dollars. Prevail Therapeutics employs 66 staff and has a market cap (total outstanding shares value) of USD$343.5 million.
|Latest market close||USD$10.05|
|52-week range||USD$9.02 - USD$19.96|
|50-day moving average||USD$10.0929|
|200-day moving average||USD$13.1252|
|Wall St. target price||USD$22.63|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-7.8|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||N/A|
|1 month (2020-10-28)||N/A|
|3 months (2020-08-28)||N/A|
|6 months (2020-05-28)||N/A|
|1 year (2019-11-27)||N/A|
|2 years (2018-11-27)||N/A|
|3 years (2017-11-27)||N/A|
|5 years (2015-11-27)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-29.11%|
|Return on equity TTM||-52.34%|
|Market capitalisation||USD$343.5 million|
TTM: trailing 12 months
There are currently 2.1 million Prevail Therapeutics shares held short by investors – that's known as Prevail Therapeutics's "short interest". This figure is 0.5% down from 2.1 million last month.
There are a few different ways that this level of interest in shorting Prevail Therapeutics shares can be evaluated.
Prevail Therapeutics's "short interest ratio" (SIR) is the quantity of Prevail Therapeutics shares currently shorted divided by the average quantity of Prevail Therapeutics shares traded daily (recently around 175936.67232598). Prevail Therapeutics's SIR currently stands at 11.78. In other words for every 100,000 Prevail Therapeutics shares traded daily on the market, roughly 11780 shares are currently held short.
However Prevail Therapeutics's short interest can also be evaluated against the total number of Prevail Therapeutics shares, or, against the total number of tradable Prevail Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Prevail Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Prevail Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.1258% of the tradable shares (for every 100,000 tradable Prevail Therapeutics shares, roughly 126 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Prevail Therapeutics.
Find out more about how you can short Prevail Therapeutics stock.
We're not expecting Prevail Therapeutics to pay a dividend over the next 12 months.
Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.
Everything we know about the Sabic IPO, plus information on how to buy in.
Everything we know about the Compass IPO, plus information on how to buy in.
Everything we know about the Marqeta IPO, plus information on how to buy in.
Everything we know about the Pharming Group N.V. IPO, plus information on how to buy in.
Everything we know about the Metromile IPO, plus information on how to buy in.
Everything we know about the CN Energy Group IPO, plus information on how to buy in.
Everything we know about the Huadi International Group IPO, plus information on how to buy in.
Everything we know about the 908 Devices IPO, plus information on how to buy in.
Steps to owning and managing LEGH, with 24-hour and historical pricing before you buy.
Steps to owning and managing LAKE, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.